Clinical Core of the Alzheimer's Disease Neuroimaging Initiative: progress and plans.
The Clinical Core of the Alzheimer's Disease Neuroimaging Initiative (ADNI) has provided clinical, operational, and data management support to ADNI since its inception. This article reviews the activities and accomplishments of the core in support of ADNI aims. These include the enrollment and follow-up of more than 800 subjects in the three original cohorts: healthy controls, amnestic mild cognitive impairment (now referred to as late MCI, or LMCI), and mild Alzheimer's disease (AD) in the first phase of ADNI (ADNI 1), with baseline longitudinal, clinical, and cognitive assessments. These data, when combined with genetic, neuroimaging, and cerebrospinal fluid measures, have provided important insights into the neurobiology of the AD spectrum. Furthermore, these data have facilitated the development of novel clinical trial designs. ADNI has recently been extended with funding from an NIH Grand Opportunities (GO) award, and the new ADNI GO phase has been launched; this includes the enrollment of a new cohort, called early MCI, with milder episodic memory impairment than the LMCI group. An application for a further 5 years of ADNI funding (ADNI 2) was recently submitted. This funding would support ongoing follow-up of the original ADNI 1 and ADNI GO cohorts, as well as additional recruitment into all categories. The resulting data would provide valuable data on the earliest stages of AD, and support the development of interventions in these critically important populations.
Aisen
Paul S
PS
Department of Neurosciences, University of California San Diego, CA, USA. paisen@ucsd.edu
Petersen
Ronald C
RC
Donohue
Michael C
MC
Gamst
Anthony
A
Raman
Rema
R
Thomas
Ronald G
RG
Walter
Sarah
S
Trojanowski
John Q
JQ
Shaw
Leslie M
LM
Beckett
Laurel A
LA
Jack
Clifford R
CR
Jagust
William
W
Toga
Arthur W
AW
Saykin
Andrew J
AJ
Morris
John C
JC
Green
Robert C
RC
Weiner
Michael W
MW
D000368:Aged; D000369:Aged, 80 and over; D000544:Alzheimer Disease / Q000134:cerebrospinal fluid / Q000175:diagnosis* / Q000235:genetics; D001921:Brain / Q000000981:diagnostic imaging / Q000473:pathology; D002986:Clinical Trials as Topic / Q000379:methods / Q000706:statistics & numerical data; D003072:Cognition Disorders / Q000000981:diagnostic imaging / Q000473:pathology; D003952:Diagnostic Imaging; D018450:Disease Progression; D005260:Female; D006624:Hippocampus / Q000000981:diagnostic imaging / Q000473:pathology; D006801:Humans; D008297:Male; D008609:Mental Status Schedule; D009483:Neuropsychological Tests; D016730:Program Development; D011877:Radionuclide Imaging
Lancet. 2006 Apr 15;367(9518):1262-70
16631882
Neurology. 2010 Jan 19;74(3):201-9
20042704
Arch Neurol. 2009 Dec;66(12):1447-55
20008648
Neurology. 2001 May 8;56(9):1143-53
11342678
J Am Geriatr Soc. 2005 Apr;53(4):695-9
15817019
Alzheimers Res Ther. 2009 Jul 09;1(1):2
19674435
BMC Med. 2009 Feb 19;7:7
19228370
Neuropsychology. 2008 Jul;22(4):531-44
18590364
Lancet Neurol. 2010 Jan;9(1):4-5
20083022
Lancet Neurol. 2010 Jan;9(1):119-28
20083042